2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1589

Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery
Abstract Number: 1590

Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus
Abstract Number: 1591

Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophophosphamide
Abstract Number: 1592

Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Abstract Number: 1593

Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality
Abstract Number: 1594

High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE
Abstract Number: 1595

Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus
Abstract Number: 1596

Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients
Abstract Number: 1597

Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes
Abstract Number: 1598

Disability Among Subtypes of SLE
Abstract Number: 1599

The Impact of Body Mass Index Variability in Systemic Lupus Erythematosus
Abstract Number: 1600

Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus
Abstract Number: 1601

Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus
Abstract Number: 1602

Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 1603

Stroke Clusters in SLE by Lupus Autoantibodies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].